In this context, the role of TWEAK in the pathophysiology of pancreatic cancer is of especial interest, as it has been demonstrated that pronounced therapeutic effects are achievable with soluble TWEAK-antibodies in a variety of disease models [28]. The gene discussed is TNFSF12; the disease is pancreatic neoplasm.